A Long-term Safety Study for Long-acting Injectable Risperidone in Schizophrenia or Schizoaffective Disorder Patients.
Status:
Completed
Trial end date:
2005-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to document the long-term safety of 25, 37.5, or 50 mg
long-acting injectable risperidone given via injection to the gluteal muscle every 2 weeks to
subjects with schizophrenia or schizoaffective disorder.